DocSym
β
Searchsearch
Search
(P94.0) Transient neonatal myasthenia gravis
More details coming soon
129 281 in individuals diagnosis transient neonatal myasthenia gravis confirmed
1 566 deaths with diagnosis transient neonatal myasthenia gravis
1% mortality rate associated with the disease transient neonatal myasthenia gravis
Diagnosis transient neonatal myasthenia gravis is diagnosed Men are 13.32% more likely than Women
73 253
Men receive the diagnosis transient neonatal myasthenia gravis
963 (1.3 %)Died from this diagnosis.
100
95
90
85
80
75
70
65
60
55
50
45
40
35
30
25
20
15
10
5
0
56 028
Women receive the diagnosis transient neonatal myasthenia gravis
603 (1.1 %)Died from this diagnosis.
Risk Group for the Disease transient neonatal myasthenia gravis - Men and Women aged 0
In Men diagnosis is most often set at age 0-5, 20-24, 35-39
Less common in men the disease occurs at Age 5-19, 25-34, 40-95+Less common in women the disease occurs at Age 5-9, 15-95+
In Women diagnosis is most often set at age 0-5, 10-14
Disease Features transient neonatal myasthenia gravis
Absence or low individual and public risk
Transient neonatal myasthenia gravis - what does this mean
Transient neonatal myasthenia gravis is an autoimmune disorder that occurs when the mother's antibodies cross the placenta and attack the baby's acetylcholine receptors, resulting in muscle weakness and fatigue. it is typically seen in newborns and usually resolves within several weeks or months without treatment.
What happens during the disease - transient neonatal myasthenia gravis
Transient neonatal myasthenia gravis is caused by the transfer of maternal autoantibodies to the fetus during pregnancy. these autoantibodies interfere with the normal functioning of the fetal neuromuscular junction, leading to decreased muscle function and weakness. this can result in respiratory distress, feeding difficulties, and even death if not treated promptly.
Clinical Pattern
More details coming soon
How does a doctor diagnose
- Neuromuscular testing
- Blood tests
- Electromyography (EMG)
- Single-fiber EMG
- Repetitive nerve stimulation
- Immunoglobulin G (IgG) testing
- Genetic testing
- MRI of the brain
Treatment and Medical Assistance
Main Goal: To reduce the symptoms of transient neonatal myasthenia gravis
- Administering intravenous immunoglobulin (IVIG)
- Administering plasmapheresis
- Administering corticosteroids
- Administering anticholinesterase drugs
- Providing adequate nutrition and hydration
- Monitoring vital signs
- Providing respiratory support
- Providing physical therapy
- Providing occupational therapy
- Providing speech therapy
10 Days of Hospitalization Required
Average Time for Outpatient Care Not Established
Transient neonatal myasthenia gravis - Prevention
Transient neonatal myasthenia gravis is best prevented by ensuring proper prenatal care and monitoring for any signs of maternal myasthenia gravis, as well as avoiding any medications that may increase the risk of the disease in the newborn.